Featured MNV Articles:
|Notable Tuesday Option Activity: UPS, BEAT, KNX
Tuesday, July 24, 3:16 PM ET, by Market News Video Staff
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume ...
BioTelemetry Reaches Analyst Target Price
Friday, July 27, 8:41 AM ET, by Market News Video Staff
In recent trading, shares of BioTelemetry Inc (BEAT) have crossed above the average analyst 12-month ...
First Week of November 16th Options Trading For Varex Imaging (VREX)
Friday, July 27, 10:58 AM ET, by Market News Video Staff
Investors in Varex Imaging Corp (VREX) saw new options become available this week, for the ...
December 2019 Options Now Available For BioTelemetry (BEAT)
Monday, July 30, 10:53 AM ET, by Market News Video Staff
Investors in BioTelemetry Inc (BEAT) saw new options begin trading today, for the December 2019 ...
Notable Wednesday Option Activity: DXCM, BEAT, CLH
Wednesday, August 1, 3:22 PM ET, by Market News Video Staff
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy ...
Look Under The Hood: IHI Has 13% Upside
By Dividend Channel Staff, Thursday, October 11, 7:45 AM ET
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Medical Devices ETF (NYSE:IHI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $235.22 per unit.
With IHI trading at a recent price near $208.84 per unit, that means that analysts see 12.63% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IHI's underlying holdings with notable upside to their analyst target prices are TransEnterix Inc (AMEX:TRXC), BioTelemetry Inc (NASDAQ:BEAT), and Varex Imaging Corp (NASDAQ:VREX). Although TRXC has traded at a recent price of $4.51/share, the average analyst target is 38.58% higher at $6.25/share. Similarly, BEAT has 26.57% upside from the recent share price of $52.41 if the average analyst target price of $66.33/share is reached, and analysts on average are expecting VREX to reach a target price of $31.50/share, which is 24.75% above the recent price of $25.25. Below is a twelve month price history chart comparing the stock performance of TRXC, BEAT, and VREX:
Below is a summary table of the current analyst target prices discussed above:
|Name ||Symbol ||Recent Price ||Avg. Analyst 12-Mo. Target ||% Upside to Target|
|iShares U.S. Medical Devices ETF ||IHI ||$208.84 ||$235.22 ||12.63%|
|TransEnterix Inc ||TRXC ||$4.51 ||$6.25 ||38.58%|
|BioTelemetry Inc ||BEAT ||$52.41 ||$66.33 ||26.57%|
|Varex Imaging Corp ||VREX ||$25.25 ||$31.50 ||24.75%|
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on TRXC — FREE
Get the latest Zacks research report on BEAT — FREE
Get the latest Zacks research report on VREX — FREE
This Article's Word Cloud: